Business Context and Reporting Period
Kura Oncology, Inc. (KURA) filed a Form 8-K on August 5, 2021, to announce its financial results for the second quarter ended June 30, 2021, and to provide a corporate update. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing states that the information contained in the referenced press release is furnished but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
The filing indicates that a corporate update was provided alongside the financial results, but the specific content of the guidance, outlook, management commentary, risks, contingencies, or unusual items is not included in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2021) for actual Q2 2021 financial figures.
- Verify the company's cash runway and burn rate, as these are critical for a clinical-stage oncology company not reporting revenue in this summary.
- Confirm the status of clinical trials and regulatory milestones mentioned in the corporate update.
- Check for any dilutive financing activities or debt covenants discussed in the full press release.